{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T13:03:38Z","timestamp":1793970218705,"version":"4.8.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"7871","license":[{"start":{"date-parts":[[2021,7,8]],"date-time":"2021-07-08T00:00:00Z","timestamp":1625702400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,7,8]],"date-time":"2021-07-08T00:00:00Z","timestamp":1625702400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nature"],"published-print":{"date-parts":[[2021,8,12]]},"DOI":"10.1038\/s41586-021-03777-9","type":"journal-article","created":{"date-parts":[[2021,7,8]],"date-time":"2021-07-08T12:03:27Z","timestamp":1625745807000},"page":"276-280","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1829,"title":["Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization"],"prefix":"10.1038","volume":"596","author":[{"given":"Delphine","family":"Planas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Veyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8351-1142","authenticated-orcid":false,"given":"Artem","family":"Baidaliuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Staropoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Guivel-Benhassine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6674-8850","authenticated-orcid":false,"given":"Maaran Michael","family":"Rajah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyril","family":"Planchais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8995-3614","authenticated-orcid":false,"given":"Fran\u00e7oise","family":"Porrot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Robillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Puech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthieu","family":"Prot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Floriane","family":"Gallais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Gantner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lie","family":"Velay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Le Guen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Najiby","family":"Kassis-Chikhani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhiaeddine","family":"Edriss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Belec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aymeric","family":"Seve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Courtellemont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"P\u00e9r\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2264-4822","authenticated-orcid":false,"given":"Laurent","family":"Hocqueloux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samira","family":"Fafi-Kremer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Prazuck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo","family":"Mouquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3952-4261","authenticated-orcid":false,"given":"Timoth\u00e9e","family":"Bruel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8420-7743","authenticated-orcid":false,"given":"Etienne","family":"Simon-Lori\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9953-7988","authenticated-orcid":false,"given":"Felix A.","family":"Rey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0729-1475","authenticated-orcid":false,"given":"Olivier","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,8]]},"reference":[{"key":"3777_CR1","doi-asserted-by":"publisher","unstructured":"Yadav, P. D. et al. Neutralization of variant under investigation B.1.617 with sera of BBV152 vaccinees. Clin. Infect. Dis. https:\/\/doi.org\/10.1093\/cid\/ciab411 (2021).","DOI":"10.1093\/cid\/ciab411"},{"key":"3777_CR2","doi-asserted-by":"publisher","unstructured":"Ferreira, I. et al. SARS-CoV-2 B.1.617 emergence and sensitivity to vaccine-elicited antibodies. Preprint at https:\/\/doi.org\/10.1101\/2021.05.08.443253 (2021).","DOI":"10.1101\/2021.05.08.443253"},{"key":"3777_CR3","doi-asserted-by":"publisher","unstructured":"Hoffmann, M. et al. SARS-CoV-2 variant B.1.617 is resistant to Bamlanivimab and evades antibodies induced by infection and vaccination. Cell Rep. https:\/\/doi.org\/10.1016\/j.celrep.2021.109415 (2021).","DOI":"10.1016\/j.celrep.2021.109415"},{"key":"3777_CR4","doi-asserted-by":"publisher","unstructured":"Cherian, S. et al. Convergent evolution of SARS-CoV-2 spike mutations, L452R, E484Q and P681R, in the second wave of COVID-19 in Maharashtra, India. Preprint at https:\/\/doi.org\/10.1101\/2021.04.22.440932 (2021).","DOI":"10.1101\/2021.04.22.440932"},{"key":"3777_CR5","doi-asserted-by":"publisher","unstructured":"Edara, V.-V. et al. Infection and vaccine-induced neutralizing-antibody responses to the SARS-CoV-2 B.1.617 variants. New Eng. J. Med. https:\/\/doi.org\/10.1056\/NEJMc2107799 (2021).","DOI":"10.1056\/NEJMc2107799"},{"key":"3777_CR6","unstructured":"Public Health England. Variants: distribution of case data, 11 June 2021. https:\/\/www.gov.uk\/government\/publications\/covid-19-variants-genomically-confirmed-case-numbers\/variants-distribution-of-case-data-11-june-2021 (2021)."},{"key":"3777_CR7","doi-asserted-by":"publisher","unstructured":"Tada, T. et al. The spike proteins of SARS-CoV-2 B.1.617 and B.1.618 variants identified in India provide partial resistance to vaccine-elicited and therapeutic monoclonal antibodies. Preprint at https:\/\/doi.org\/10.1101\/2021.05.14.444076 (2021).","DOI":"10.1101\/2021.05.14.444076"},{"key":"3777_CR8","doi-asserted-by":"publisher","unstructured":"Liu, J. et al. BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants. Nature https:\/\/doi.org\/10.1038\/s41586-021-03693-y (2021).","DOI":"10.1038\/s41586-021-03693-y"},{"key":"3777_CR9","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1016\/S0140-6736(21)01290-3","volume":"397","author":"EC Wall","year":"2021","unstructured":"Wall, E. C. et al. Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination. Lancet 397, 2331\u20132333 (2021).","journal-title":"Lancet"},{"key":"3777_CR10","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2020106267","volume":"39","author":"J Buchrieser","year":"2020","unstructured":"Buchrieser, J. et al. Syncytia formation by SARS-CoV-2-infected cells. EMBO J. 39, e106267 (2020).","journal-title":"EMBO J."},{"key":"3777_CR11","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/s41591-021-01318-5","volume":"27","author":"D Planas","year":"2021","unstructured":"Planas, D. et al. Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies. Nat. Med. 27, 917\u2013924 (2021).","journal-title":"Nat. Med."},{"key":"3777_CR12","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1038\/s41564-020-0770-5","volume":"5","author":"A Rambaut","year":"2020","unstructured":"Rambaut, A. et al. A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology. Nat. Microbiol. 5, 1403\u20131407 (2020).","journal-title":"Nat. Microbiol."},{"key":"3777_CR13","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.chom.2021.02.020","volume":"29","author":"JA Plante","year":"2021","unstructured":"Plante, J. A. et al. The variant gambit: COVID-19\u2019s next move. Cell Host Microbe 29, 508\u2013515 (2021).","journal-title":"Cell Host Microbe"},{"key":"3777_CR14","unstructured":"Centers for Disease Control and Prevention. SARS-CoV-2 variant classifications and definitions. https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/cases-updates\/variant-surveillance\/variant-info.html (2021)."},{"key":"3777_CR15","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1016\/j.cell.2021.03.028","volume":"184","author":"M McCallum","year":"2021","unstructured":"McCallum, M. et al. N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2. Cell 184, 2332\u20132347 (2021).","journal-title":"Cell"},{"key":"3777_CR16","doi-asserted-by":"publisher","first-page":"100255","DOI":"10.1016\/j.xcrm.2021.100255","volume":"2","author":"TN Starr","year":"2021","unstructured":"Starr, T. N., Greaney, A. J., Dingens, A. S. & Bloom, J. D. Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016. Cell Rep. Med. 2, 100255 (2021).","journal-title":"Cell Rep. Med."},{"key":"3777_CR17","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/s41586-020-2852-1","volume":"588","author":"CO Barnes","year":"2020","unstructured":"Barnes, C. O. et al. SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies. Nature 588, 682\u2013687 (2020).","journal-title":"Nature"},{"key":"3777_CR18","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/s41577-021-00542-x","volume":"21","author":"PC Taylor","year":"2021","unstructured":"Taylor, P. C. et al. Neutralizing monoclonal antibodies for treatment of COVID-19. Nat. Rev. Immunol. 21, 382\u2013393 (2021).","journal-title":"Nat. Rev. Immunol."},{"key":"3777_CR19","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1126\/science.abf9302","volume":"371","author":"TN Starr","year":"2021","unstructured":"Starr, T. N. et al. Prospective mapping of viral mutations that escape antibodies used to treat COVID-19. Science 371, 850\u2013854 (2021).","journal-title":"Science"},{"key":"3777_CR20","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/s41586-020-2571-7","volume":"584","author":"L Liu","year":"2020","unstructured":"Liu, L. et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584, 450\u2013456 (2020).","journal-title":"Nature"},{"key":"3777_CR21","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/s41586-021-03398-2","volume":"593","author":"P Wang","year":"2021","unstructured":"Wang, P. et al. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature 593, 130\u2013135 (2021).","journal-title":"Nature"},{"key":"3777_CR22","doi-asserted-by":"publisher","first-page":"102915","DOI":"10.1016\/j.ebiom.2020.102915","volume":"59","author":"S Fafi-Kremer","year":"2020","unstructured":"Fafi-Kremer, S. et al. Serologic responses to SARS-CoV-2 infection among hospital staff with mild disease in eastern France. EBioMedicine 59, 102915 (2020).","journal-title":"EBioMedicine"},{"key":"3777_CR23","doi-asserted-by":"publisher","unstructured":"Gallais, F. et al. Anti-SARS-CoV-2 antibodies persist for up to 13 months and reduce risk of reinfection. Preprint at https:\/\/doi.org\/10.1101\/2021.05.07.21256823 (2021).","DOI":"10.1101\/2021.05.07.21256823"},{"key":"3777_CR24","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1056\/NEJMc2101667","volume":"384","author":"F Krammer","year":"2021","unstructured":"Krammer, F. et al. Antibody responses in seropositive persons after a single dose of SARS-CoV-2 mRNA vaccine. N. Engl. J. Med. 384, 1372\u20131374 (2021).","journal-title":"N. Engl. J. Med."},{"key":"3777_CR25","doi-asserted-by":"crossref","unstructured":"Khoury, D. S. et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat. Med. (2021).","DOI":"10.1038\/s41591-021-01377-8"},{"key":"3777_CR26","doi-asserted-by":"publisher","unstructured":"Bernal, J. L. et al. Effectiveness of COVID-19 vaccines against the B.1.617.2 variant. Preprint at https:\/\/doi.org\/10.1101\/2021.05.22.21257658 (2021).","DOI":"10.1101\/2021.05.22.21257658"},{"key":"3777_CR27","doi-asserted-by":"publisher","first-page":"4121","DOI":"10.1093\/bioinformatics\/bty407","volume":"34","author":"J Hadfield","year":"2018","unstructured":"Hadfield, J. et al. Nextstrain: real-time tracking of pathogen evolution. Bioinformatics 34, 4121\u20134123 (2018).","journal-title":"Bioinformatics"},{"key":"3777_CR28","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1126\/science.abd4251","volume":"369","author":"Y Cai","year":"2020","unstructured":"Cai, Y. et al. Distinct conformational states of SARS-CoV-2 spike protein. Science 369, 1586\u20131592 (2020).","journal-title":"Science"},{"key":"3777_CR29","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.jim.2015.04.010","volume":"422","author":"V Lorin","year":"2015","unstructured":"Lorin, V. & Mouquet, H. Efficient generation of human IgA monoclonal antibodies. J. Immunol. Methods 422, 102\u2013110 (2015).","journal-title":"J. Immunol. Methods"},{"key":"3777_CR30","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.3390\/v12091006","volume":"12","author":"PL Tzou","year":"2020","unstructured":"Tzou, P. L. et al. Coronavirus antiviral research database (CoV-RDB): an online database designed to facilitate comparisons between candidate anti-coronavirus compounds. Viruses 12, 1006 (2020).","journal-title":"Viruses"}],"container-title":["Nature"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41586-021-03777-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-021-03777-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-021-03777-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,3]],"date-time":"2023-01-03T06:12:39Z","timestamp":1672726359000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41586-021-03777-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,8]]},"references-count":30,"journal-issue":{"issue":"7871","published-print":{"date-parts":[[2021,8,12]]}},"alternative-id":["3777"],"URL":"https:\/\/doi.org\/10.1038\/s41586-021-03777-9","relation":{},"ISSN":["0028-0836","1476-4687"],"issn-type":[{"value":"0028-0836","type":"print"},{"value":"1476-4687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,8]]},"assertion":[{"value":"26 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.P., H.M., O.S, T.B. and F.A.R. have a pending patent application for the anti-RBD monoclonal antibodies described in the present study (PCT\/FR2021\/070522). F.A.R. is a member of the Board of MELETIOS Therapeutics and of the Scientific Advisory Board of eureKARE. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}